Ignite Creation Date:
2024-05-05 @ 11:08 AM
Last Modification Date:
2024-10-26 @ 9:03 AM
Study NCT ID:
NCT00002409
Status:
COMPLETED
Last Update Posted:
2005-06-24
First Post:
1999-11-02
Brief Title:
The Effect of Teaching HIV-Infected Patients About HIV and Treatment
Sponsor:
Glaxo Wellcome
Organization:
NIH AIDS Clinical Trials Information Service
Study Overview
Official Title:
A Phase IIIB Open-Label Randomized Study of the Effect of an Education Intervention on Virological Outcomes Adherence Immunological Outcome and Health Outcomes in HIV-Infected Subjects From Under-Represented Populations Treated With Triple Nucleoside Therapy Combivir Lamivudine 150 MgZidovudine 300 Mg PO BID Plus Abacavir 300 Mg PO BID for Twenty-Four Weeks
Status:
COMPLETED
Status Verified Date:
1999-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to see if an HIV-education course can help under-represented HIV-infected patients This study examines the areas of faithfulness to drug regimen level of HIV in the blood and health status
Detailed Description:
Following initial screening eligible patients are treated with open-label Combivir plus abacavir for 24 weeks Patients are randomized to undergo the education intervention Tools for Health and Empowerment THE course plus counseling or routine counseling only control group Measurements and evaluations for assessment of immunologic effects adherence and health outcomes are performed at entry Day 1 and at Weeks 2 5 8 12 16 and 24
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| NZTA 4006 | None | None | None |